How Effective Is Dupixent for Moderate-to-Severe Eczema?
Dupixent (dupilumab) shows clear success in clinical trials for adults and adolescents with moderate-to-severe atopic dermatitis (eczema) unresponsive to topical treatments. In pivotal phase 3 trials like SOLO 1 and SOLO 2, 37-38% of patients achieved clear or almost clear skin (IGA 0/1 score) at 16 weeks, compared to 10% on placebo. Itch reduction hit 44-48% (≥4-point improvement on Peak Pruritus NRS), versus 12% on placebo.[1][2]
Real-world data aligns: A 2022 study of 200+ patients reported 60-70% reaching IGA 0/1 or EASI-75 (75% eczema area/severity improvement) by week 16, with sustained results up to a year.[3]
What Do Longer-Term Studies Show?
In the open-label extension CHRONOS trial, 36% maintained IGA 0/1 at 52 weeks on 300mg every two weeks, rising to 46% at 176 weeks with continuous use. EASI-75 rates exceeded 70% long-term, indicating durable response without tachyphylaxis.[1][4]
Success in Kids with Eczema?
For ages 6-11 (LIBERTY AD PED OLE trial), 54% hit IGA 0/1 and 69% EASI-75 at week 16 on weight-based dosing. Adolescent data (ages 12+) mirrors adult rates at 24-37% for IGA 0/1.[1][5]
Why Don't All Patients Respond—and What Defines 'Success'?
Response varies by baseline severity; severe cases see 20-30% IGA 0/1 but higher itch relief (up to 60%). Primary endpoints use IGA (investigator-assessed skin clearance) and EASI (quantitative lesion reduction). About 20-30% are non-responders, often due to high IgE or prior biologics failure. Combination with topicals boosts rates by 10-15%.[1][6]
Common Side Effects Impacting Success?
Injection-site reactions (10-20%), conjunctivitis (10%), and herpes infections (5%) occur but rarely cause discontinuation (2-5%). These drop adherence below 90% in year 1, affecting perceived success.[1][2]
How Does Dupixent Stack Up Against Other Eczema Treatments?
| Treatment | IGA 0/1 at 16 Weeks | EASI-75 at 16 Weeks | Notes |
|-----------|---------------------|---------------------|-------|
| Dupixent | 37-44% | 44-68% | Dual IL-4/IL-13 blocker; best for itch/skin[1][2] |
| Abrocitinib (Cibinqo) | 39-43% | 62-71% | JAK inhibitor; faster onset, more infections[7] |
| Upadacitinib (Rinvoq) | 44-60% | 70-80% | JAK; higher efficacy, black-box warnings[8] |
| Crisaborole (Eucrisa) | 32% | N/A | PDE4 topical; milder cases only[9] |
Dupixent leads in long-term data but trails JAKs in speed for some.
Who Makes Dupixent and What's the Cost?
Sanofi and Regeneron co-develop/market it. List price is $3,800-$5,000/month (U.S.), though copay cards cut patient costs to $0-25 for eligible. No generic yet; key patents expire 2031-2033.10
[1]: Dupixent Prescribing Information, Regeneron/Sanofi (dupixent.com)
[2]: Simpson et al., NEJM 2016; SOLO trials
[3]: Thaçi et al., J Am Acad Dermatol 2022; real-world analysis
[4]: Blauvelt et al., Br J Dermatol 2020; CHRONOS
[5]: Paller et al., Lancet 2020; pediatric trials
[6]: Wollenberg et al., J Allergy Clin Immunol 2021; predictors of response
[7]: Eichenfield et al., JAAD 2021; Cibinqo trials
[8]: Guttman-Yassky et al., NEJM 2021; Rinvoq
[9]: Paller et al., NEJM 2016; Eucrisa